Literature DB >> 20031210

Molecular characterization and prognostic significance of FLT3 in CML progression.

Kyung Im Kim1, Juwon Park, Kwang-Sung Ahn, Nam-Hee Won, Byoung Kook Kim, Wan Gyoon Shin, Sung-Soo Yoon, Jung Mi Oh.   

Abstract

To characterize the molecular mechanisms involved in the transition from the chronic phase to blast crisis in chronic myelogenous leukemia (CML), gene expression profiles of leukemic cells from patients in the chronic and blast crisis phases were analyzed using an 8.7K cDNA chip and real-time PCR. A transient transfection analysis was conducted to evaluate the role of FLT3, which was significantly upregulated in the blast crisis patients. Abl and c-Kit induction was detected in K562 cells transfected with FLT3 cDNA (K562/FLT3), and Abl and c-Kit levels were reduced in K562/FLT3 cells transfected with FLT3-siRNA (K562/FLT3-siRNA). The induction of FLT3 in CML cells attenuated imatinib-induced apoptosis. The opposite effect was observed in K562/FLT3-siRNA cells. An increased level of cleaved PARP and decreased level of pro-caspase 3 were noted when K562/FLT3-siRNA cells were treated with imatinib. These findings indicate that FLT3 is associated with disease progression, despite imatinib therapy. These results may help in the prediction of disease progression in CML patients and the development of more appropriate therapeutic modalities. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20031210     DOI: 10.1016/j.leukres.2009.11.008

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

1.  A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression.

Authors:  George Giotopoulos; Louise van der Weyden; Hikari Osaki; Alistair G Rust; Paolo Gallipoli; Eshwar Meduri; Sarah J Horton; Wai-In Chan; Donna Foster; Rab K Prinjha; John E Pimanda; Daniel G Tenen; George S Vassiliou; Steffen Koschmieder; David J Adams; Brian J P Huntly
Journal:  J Exp Med       Date:  2015-08-24       Impact factor: 14.307

2.  TALENs-mediated gene disruption of FLT3 in leukemia cells: Using genome-editing approach for exploring the molecular basis of gene abnormality.

Authors:  Jue Wang; Tongjuan Li; Mi Zhou; Zheng Hu; Xiaoxi Zhou; Shiqiu Zhou; Na Wang; Liang Huang; Lei Zhao; Yang Cao; Min Xiao; Ding Ma; Pengfei Zhou; Zhen Shang; Jianfeng Zhou
Journal:  Sci Rep       Date:  2015-12-16       Impact factor: 4.379

3.  Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis.

Authors:  Huayao Li; Lijuan Liu; Jing Zhuang; Cun Liu; Chao Zhou; Jing Yang; Chundi Gao; Gongxi Liu; Changgang Sun
Journal:  Mol Genet Genomic Med       Date:  2019-08-02       Impact factor: 2.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.